Mesoblast Ltd
MESO18.410USD
+1.390+8.17%
收盘 10/03, 16:00（美东）报价延迟15分钟
2.36B总市值
亏损市盈率 TTM
关于 Mesoblast Ltd 公司
Mesoblast Limited 是一家总部位于澳大利亚的公司，致力于开发用于治疗严重和危及生命的炎症疾病的同种异体（现成）细胞药物。该公司利用其专有的间充质谱系细胞治疗技术平台建立了广泛的后期候选产品组合。该公司正在基于其 remestemcel-L 和 rexlemestrocel-L 同种异体基质细胞技术平台开发用于不同适应症的候选产品。Remestemcel-L 正在开发用于儿童和成人炎症疾病，包括类固醇难治性急性移植物抗宿主病和生物耐药性炎症性肠病。Rexlemestrocel-L 正在开发用于治疗晚期慢性心力衰竭 (REVASCOR) 和慢性腰痛 (MPC-06-ID)。该公司的许可方已在日本和欧洲商业化了两种产品。该公司已在欧洲和中国建立了某些 III 期资产的商业伙伴关系。
Mesoblast Ltd简介
公司代码MESO
公司名称Mesoblast Ltd
上市日期Dec 16, 2004
CEODr. Silviu Itescu
员工数量73
证券类型Depository Receipt
年结日Dec 16
公司地址L 38 55 Collins St
城市MELBOURNE
上市交易所NASDAQ Global Select Consolidated
国家Australia
邮编3000
电话61396396036
网址https://www.mesoblast.com/
公司代码MESO
上市日期Dec 16, 2004
CEODr. Silviu Itescu
Mesoblast Ltd公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+73.64%
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+73.64%
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Paul Hughes
Mr. Paul Hughes
Joint Company Secretary
Joint Company Secretary
--
--
Dr. Fiona See, Ph.D.
Dr. Fiona See, Ph.D.
Senior Vice President, Head - Translational Research
Senior Vice President, Head - Translational Research
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月18日 周四
更新时间: 9月18日 周四
持股股东
股东类型
持股股东
持股股东
占比
Gueck (William J)
5.01%
BlackRock Institutional Trust Company, N.A.
0.39%
Goldman Sachs & Company, Inc.
0.32%
Morgan Stanley & Co. International Plc
0.24%
Susquehanna International Group, LLP
0.18%
其他
93.85%
持股股东
持股股东
占比
Gueck (William J)
5.01%
BlackRock Institutional Trust Company, N.A.
0.39%
Goldman Sachs & Company, Inc.
0.32%
Morgan Stanley & Co. International Plc
0.24%
Susquehanna International Group, LLP
0.18%
其他
93.85%
股东类型
持股股东
占比
Individual Investor
5.10%
Investment Advisor
1.47%
Research Firm
0.85%
Investment Advisor/Hedge Fund
0.20%
Hedge Fund
0.14%
Bank and Trust
0.03%
其他
92.22%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
129
3.44M
2.68%
-1.12M
2025Q2
126
4.04M
3.16%
+542.30K
2025Q1
132
4.07M
3.19%
+9.28K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
2023Q2
99
982.29K
1.21%
-1.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gueck (William J)
6.42M
5.01%
+6.42M
--
Sep 12, 2025
BlackRock Institutional Trust Company, N.A.
499.00K
0.39%
-66.89K
-11.82%
Jun 30, 2025
Goldman Sachs & Company, Inc.
415.46K
0.32%
+158.32K
+61.57%
Jun 30, 2025
Morgan Stanley & Co. International Plc
313.52K
0.24%
--
--
Jun 30, 2025
Susquehanna International Group, LLP
234.59K
0.18%
-26.35K
-10.10%
Jun 30, 2025
Summit Wealth Strategies
199.29K
0.16%
+1.13K
+0.57%
Jun 30, 2025
Morgan Stanley & Co. LLC
179.44K
0.14%
-44.82K
-19.99%
Jun 30, 2025
UBS Financial Services, Inc.
160.04K
0.12%
+22.70K
+16.53%
Jun 30, 2025
Aperio Group, LLC
135.17K
0.11%
+2.68K
+2.02%
Jun 30, 2025
Marex Group plc
100.00K
0.08%
+100.00K
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月2日 周四
更新时间: 10月2日 周四
机构名称
占比
iShares Biotechnology ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
ActivePassive International Equity ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
公告日期
类型
比率
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
